Literature DB >> 11223539

Hexosaminidase-altered aberrant crypts, carrying decreased hexosaminidase alpha and beta subunit mRNAs, in colon of 1,2-dimethylhydrazine-treated rats.

T Tsukamoto1, H Fukami, S Yamanaka, A Yamaguchi, H Nakanishi, H Sakai, I Aoki, M Tatematsu.   

Abstract

Aberrant crypt foci (ACF), consisting of morphologically irregular crypts, are thought to be precancerous lesions for colon cancers. For their molecular analysis, it is necessary to avoid contamination with adjacent normal crypts and stromal cells. Decreased hexosaminidase activity in ACF, which has been histochemically demonstrated, was used in the present study to classify isolated crypts in combination with morphological changes. The length, rim diameter, and width (average SD, microm) of hexosaminidase-positive (Hex + ) crypts were 238.6 +/- 40.4, 89.5 +/- 22.9, and 57.6 +/- 14.0, respectively. For hexosaminidase-negative (Hex - ) crypts, the values were 314.4 +/- 77.8, 140.3 +/- 45.7, and 97.3 +/- 34.7, the width being 1.69 times greater (P < 0.0001). Crypts wider than 115 microm (approximately 2 times the average size of Hex + crypts) were all from ACF, judging from hexosaminidase staining. To analyze transcription levels of Hex alpha and beta subunits (Hexa and Hexb, respectively), real-time relative quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis was performed using the LightCycler system. In aberrant crypts, both Hexa and Hexb were significantly down-regulated to 0.266 (P < 0.002) and 0.131 (P < 0.001) units, respectively, compared with those in morphologically normal crypts, with beta-actin as the internal standard. This decrease could be a molecular marker for precancerous enzyme-altered ACF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11223539      PMCID: PMC5926690          DOI: 10.1111/j.1349-7006.2001.tb01072.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  47 in total

1.  In situ hybridization with non-radioactive digoxigenin-11-UTP-labeled cRNA probes: localization of developmentally regulated mouse tenascin mRNAs.

Authors:  T Tsukamoto; M Kusakabe; Y Saga
Journal:  Int J Dev Biol       Date:  1991-03       Impact factor: 2.203

2.  Real time quantitative PCR.

Authors:  C A Heid; J Stevens; K J Livak; P M Williams
Journal:  Genome Res       Date:  1996-10       Impact factor: 9.043

3.  Chemopreventive agents-induced regression of azoxymethane-induced aberrant crypt foci with the recovery of hexosaminidase activity.

Authors:  L Tao; K Li; M A Pereira
Journal:  Carcinogenesis       Date:  1997-07       Impact factor: 4.944

4.  Continuous fluorescence monitoring of rapid cycle DNA amplification.

Authors:  C T Wittwer; M G Herrmann; A A Moss; R P Rasmussen
Journal:  Biotechniques       Date:  1997-01       Impact factor: 1.993

5.  Immunohistochemical demonstration of induction of pyloric glands with low pepsinogen 1 (Pg 1) content in rat stomach by N-methyl-N'-nitro-N-nitrosoguanidine.

Authors:  M Tatematsu; C Furihata; Y Mera; T Shirai; T Matsushima; N Ito
Journal:  Jpn J Cancer Res       Date:  1986-03

6.  Enhancing effects of various gastric carcinogens on development of pepsinogen-altered pyloric glands in rats.

Authors:  M Tatematsu; K Ozaki; M Mutai; Y Shichino; C Furihata; N Ito
Journal:  Carcinogenesis       Date:  1990-11       Impact factor: 4.944

Review 7.  Role of aberrant crypt foci in understanding the pathogenesis of colon cancer.

Authors:  R P Bird
Journal:  Cancer Lett       Date:  1995-06-29       Impact factor: 8.679

8.  Enzyme-altered foci in colons of carcinogen-treated rats.

Authors:  B J Barrow; M A O'Riordan; T A Stellato; B M Calkins; T P Pretlow
Journal:  Cancer Res       Date:  1990-03-15       Impact factor: 12.701

9.  Immunohistochemical demonstration of pyloric gland-type cells with low-pepsinogen isozyme 1 in preneoplastic and neoplastic tissues of rat stomachs treated with N-methyl-N'-nitro-N-nitrosoguanidine.

Authors:  M Tatematsu; C Furihata; T Katsuyama; Y Mera; T Inoue; T Matsushima; N Ito
Journal:  J Natl Cancer Inst       Date:  1987-04       Impact factor: 13.506

10.  Isoenzymes of beta-hexosaminidase from normal rat colon and colonic carcinoma.

Authors:  M G Brattain; C Green; P M Kimball; M Marks; M Khaled
Journal:  Cancer Res       Date:  1979-10       Impact factor: 12.701

View more
  5 in total

1.  Down-regulation of a gastric transcription factor, Sox2, and ectopic expression of intestinal homeobox genes, Cdx1 and Cdx2: inverse correlation during progression from gastric/intestinal-mixed to complete intestinal metaplasia.

Authors:  Tetsuya Tsukamoto; Kenichi Inada; Harunari Tanaka; Tsutomu Mizoshita; Mami Mihara; Toshikazu Ushijima; Yoshitaka Yamamura; Shigeo Nakamura; Masae Tatematsu
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-04       Impact factor: 4.553

2.  Dose-dependent roles for canonical Wnt signalling in de novo crypt formation and cell cycle properties of the colonic epithelium.

Authors:  Akihiro Hirata; Jochen Utikal; Satoshi Yamashita; Hitomi Aoki; Akira Watanabe; Takuya Yamamoto; Hideyuki Okano; Nabeel Bardeesy; Takahiro Kunisada; Toshikazu Ushijima; Akira Hara; Rudolf Jaenisch; Konrad Hochedlinger; Yasuhiro Yamada
Journal:  Development       Date:  2013-01-01       Impact factor: 6.868

3.  Expression of small intestinal and colonic phenotypes in complete intestinal metaplasia of the human stomach.

Authors:  Harunari Tanaka; Tetsuya Tsukamoto; Tsutomu Mizoshita; Ken-ichi Inada; Naotaka Ogasawara; Xueyuan Cao; Sosuke Kato; Takashi Joh; Masae Tatematsu
Journal:  Virchows Arch       Date:  2005-08-09       Impact factor: 4.064

Review 4.  Mouse models for the study of colon carcinogenesis.

Authors:  Daniel W Rosenberg; Charles Giardina; Takuji Tanaka
Journal:  Carcinogenesis       Date:  2008-11-26       Impact factor: 4.944

5.  Differential effects of partial hepatectomy and carbon tetrachloride administration on induction of liver cell foci in a model for detection of initiation activity.

Authors:  H Sakai; T Tsukamoto; M Yamamoto; N Shirai; T Iidaka; T Yanai; T Masegi; M Tatematsu
Journal:  Jpn J Cancer Res       Date:  2001-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.